GLP-1 Market
LLY $1283.66 ▲ +3.5% NVO $39.35 ▲ +2.4% PFE $30.11 ▲ +2.3% VKTX $26.71 ▲ +6.6% KLRA $12.89 ▲ +12.8% GPCR $22.88 ▲ +4.0% RHHBY $59.11 ▲ +3.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

WS016

WS016

Company
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for WS016 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07251309

    A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

    Not yet reported Waterstone Pharmaceutical (Wuhan) Co., LTD. 420 participants Est. completion 2026-11 50 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Recruiting NCT NCT07881965

    A Two-Part, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

    Not yet reported Waterstone Pharmaceutical (Wuhan) Co., LTD. 300 participants Est. completion 2029-03-30 50 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Status unknown NCT NCT06277128

    A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.

    Not yet reported Waterstone Pharmaceutical (Wuhan) Co., LTD. 140 participants Est. completion 2024-08-04 26 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT06281470

    The Safety and Tolerability of WS016 in Healthy Chinese Volunteers

    Not yet reported Waterstone Pharmaceutical (Wuhan) Co., LTD. 66 participants Est. completion 2023-06-15 1 site Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.